Loading…
Mupirocin Resistance in Patients Colonized with Methicillin-Resistant Staphylococcus aureus in a Surgical Intensive Care Unit
Background. Nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) can be a precursor to serious infection, and decolonization with topical mupirocin has been studied as a means of preventing clinical infection. Mupirocin resistance in patients with MRSA has been reported, usuall...
Saved in:
Published in: | Clinical infectious diseases 2007-09, Vol.45 (5), p.541-547 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c451t-96bcf58862b04bc499663fa701e986612fee250de2f124d611367739110f467b3 |
---|---|
cites | cdi_FETCH-LOGICAL-c451t-96bcf58862b04bc499663fa701e986612fee250de2f124d611367739110f467b3 |
container_end_page | 547 |
container_issue | 5 |
container_start_page | 541 |
container_title | Clinical infectious diseases |
container_volume | 45 |
creator | Jones, Jeffrey C. Rogers, Theodore J. Brookmeyer, Peter Dunne, William Michael Storch, Gregory A. Coopersmith, Craig M. Fraser, Victoria J. Warren, David K. |
description | Background. Nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) can be a precursor to serious infection, and decolonization with topical mupirocin has been studied as a means of preventing clinical infection. Mupirocin resistance in patients with MRSA has been reported, usually in the context of widespread mupirocin use. Methods. Patients admitted to a surgical intensive care unit (SICU) had nasal swab cultures for MRSA performed at admission, weekly, and at discharge in an active surveillance program. Collected MRSA isolates were tested for mupirocin resistance, and molecular analysis was performed. Clinical data on the characteristics and outcomes of the patients who stayed in the SICU for >48 h were collected prospectively. Results. Of the 302 MRSA isolates available for testing, 13.2% were resistant to mupirocin, with 8.6% having high-level resistance (minimum inhibitory concentration, ⩾512 µg/mL) and 4.6% having low-level resistance (minimum inhibitory concentration, 8–256 µg/mL). Patients admitted to the SICU for >48 h who were colonized with mupirocin-resistant MRSA were more likely to have been admitted to our hospital during the previous year (P = .016), were older (P = .009), and had higher in-hospital mortality (16% vs. 33%; P = .027), compared with patients colonized with mupirocin-susceptible MRSA. Molecular analysis of the mupirocin-resistant isolates revealed that 72.5% of isolates contained staphylococcal cassette chromosome mec II. Repetitive sequence polymerase chain reaction typing revealed that high-level mupirocin resistance was present in multiple clonal groups. The rate of mupirocin use hospital-wide during the study period was 6.08 treatment-days per 1000 patient-days. Conclusions. We documented a high rate of mupirocin resistance in MRSA isolates from SICU patients, despite low levels of in-hospital mupirocin use. |
doi_str_mv | 10.1086/520663 |
format | article |
fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68144578</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4485508</jstor_id><oup_id>10.1086/520663</oup_id><sourcerecordid>4485508</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-96bcf58862b04bc499663fa701e986612fee250de2f124d611367739110f467b3</originalsourceid><addsrcrecordid>eNp1kVFrFDEUhQdRbK36C0SioG-jSSbJJI91UFvYolgL4kvIZu-4WWeTMcmoFfzvZpl1C4JPN-F-OTfn3Kp6SPALgqV4ySkWorlVHRPetLXgitwuZ8xlzWQjj6p7KW0wJkRifrc6Iq2QVElxXP2-mEYXg3UefYDkUjbeAiq39yY78DmhLgzBu1-wQj9cXqMLyGtn3TA4X_99kdFlNuP6egg2WDslZKYIpRQZgy6n-MVZM6Bzn8En9x1QZyKgK-_y_epOb4YED_b1pLp68_pjd1Yv3r09704XtWWc5FqJpe25lIIuMVtaplTx2psWEygmBKE9AOV4BbQnlK0EIY1o20YRgnsm2mVzUj2fdccYvk2Qst66ZGEYjIcwJS0kYYy3soBP_wE3YYq-_E1TohTnTLEbNRtDShF6PUa3NfFaE6x329DzNgr4eK82LbewusH28Rfg2R4wqUTUx5K-SweOYqqwancTn8xcmMb_D3s0M5uUQzxQjEnO8c5ZPbfLxuDnoW3iVy3apuX67NPn4nFB-SssdNf8AY-Xszo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219955494</pqid></control><display><type>article</type><title>Mupirocin Resistance in Patients Colonized with Methicillin-Resistant Staphylococcus aureus in a Surgical Intensive Care Unit</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Oxford Journals Online</source><creator>Jones, Jeffrey C. ; Rogers, Theodore J. ; Brookmeyer, Peter ; Dunne, William Michael ; Storch, Gregory A. ; Coopersmith, Craig M. ; Fraser, Victoria J. ; Warren, David K.</creator><creatorcontrib>Jones, Jeffrey C. ; Rogers, Theodore J. ; Brookmeyer, Peter ; Dunne, William Michael ; Storch, Gregory A. ; Coopersmith, Craig M. ; Fraser, Victoria J. ; Warren, David K.</creatorcontrib><description>Background. Nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) can be a precursor to serious infection, and decolonization with topical mupirocin has been studied as a means of preventing clinical infection. Mupirocin resistance in patients with MRSA has been reported, usually in the context of widespread mupirocin use. Methods. Patients admitted to a surgical intensive care unit (SICU) had nasal swab cultures for MRSA performed at admission, weekly, and at discharge in an active surveillance program. Collected MRSA isolates were tested for mupirocin resistance, and molecular analysis was performed. Clinical data on the characteristics and outcomes of the patients who stayed in the SICU for >48 h were collected prospectively. Results. Of the 302 MRSA isolates available for testing, 13.2% were resistant to mupirocin, with 8.6% having high-level resistance (minimum inhibitory concentration, ⩾512 µg/mL) and 4.6% having low-level resistance (minimum inhibitory concentration, 8–256 µg/mL). Patients admitted to the SICU for >48 h who were colonized with mupirocin-resistant MRSA were more likely to have been admitted to our hospital during the previous year (P = .016), were older (P = .009), and had higher in-hospital mortality (16% vs. 33%; P = .027), compared with patients colonized with mupirocin-susceptible MRSA. Molecular analysis of the mupirocin-resistant isolates revealed that 72.5% of isolates contained staphylococcal cassette chromosome mec II. Repetitive sequence polymerase chain reaction typing revealed that high-level mupirocin resistance was present in multiple clonal groups. The rate of mupirocin use hospital-wide during the study period was 6.08 treatment-days per 1000 patient-days. Conclusions. We documented a high rate of mupirocin resistance in MRSA isolates from SICU patients, despite low levels of in-hospital mupirocin use.</description><identifier>ISSN: 1058-4838</identifier><identifier>ISSN: 1537-6591</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/520663</identifier><identifier>PMID: 17682986</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - pharmacology ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Articles and Commentaries ; Bacterial diseases ; Biological and medical sciences ; Carrier State - microbiology ; Clinical outcomes ; Decolonization ; Drug resistance ; Drug Resistance, Multiple, Bacterial ; Female ; Hospital admissions ; Hospitals, Private - statistics & numerical data ; Human bacterial diseases ; Humans ; Infections ; Infectious diseases ; Intensive care ; Intensive Care Units - statistics & numerical data ; Male ; Medical sciences ; Methicillin Resistance ; Methicillin resistant staphylococcus aureus ; Microbial colonization ; Middle Aged ; Missouri - epidemiology ; Mupirocin - pharmacology ; Nose - microbiology ; Patients ; Pharmacology. Drug treatments ; Phylogeny ; Polymerase chain reaction ; Risk Factors ; Sentinel Surveillance ; Skin diseases ; Staphylococcal Infections - drug therapy ; Staphylococcal Infections - epidemiology ; Staphylococcal infections, streptococcal infections, pneumococcal infections ; Staphylococcus ; Staphylococcus aureus ; Staphylococcus aureus - classification ; Staphylococcus aureus - drug effects ; Staphylococcus aureus - genetics ; Staphylococcus infections ; Surgical intensive care units</subject><ispartof>Clinical infectious diseases, 2007-09, Vol.45 (5), p.541-547</ispartof><rights>Copyright 2007 The Infectious Diseases Society of America</rights><rights>2007 Infectious Diseases Society of America 2007</rights><rights>2008 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Sep 1, 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-96bcf58862b04bc499663fa701e986612fee250de2f124d611367739110f467b3</citedby><cites>FETCH-LOGICAL-c451t-96bcf58862b04bc499663fa701e986612fee250de2f124d611367739110f467b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4485508$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4485508$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,58238,58471</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20290974$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17682986$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jones, Jeffrey C.</creatorcontrib><creatorcontrib>Rogers, Theodore J.</creatorcontrib><creatorcontrib>Brookmeyer, Peter</creatorcontrib><creatorcontrib>Dunne, William Michael</creatorcontrib><creatorcontrib>Storch, Gregory A.</creatorcontrib><creatorcontrib>Coopersmith, Craig M.</creatorcontrib><creatorcontrib>Fraser, Victoria J.</creatorcontrib><creatorcontrib>Warren, David K.</creatorcontrib><title>Mupirocin Resistance in Patients Colonized with Methicillin-Resistant Staphylococcus aureus in a Surgical Intensive Care Unit</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>Background. Nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) can be a precursor to serious infection, and decolonization with topical mupirocin has been studied as a means of preventing clinical infection. Mupirocin resistance in patients with MRSA has been reported, usually in the context of widespread mupirocin use. Methods. Patients admitted to a surgical intensive care unit (SICU) had nasal swab cultures for MRSA performed at admission, weekly, and at discharge in an active surveillance program. Collected MRSA isolates were tested for mupirocin resistance, and molecular analysis was performed. Clinical data on the characteristics and outcomes of the patients who stayed in the SICU for >48 h were collected prospectively. Results. Of the 302 MRSA isolates available for testing, 13.2% were resistant to mupirocin, with 8.6% having high-level resistance (minimum inhibitory concentration, ⩾512 µg/mL) and 4.6% having low-level resistance (minimum inhibitory concentration, 8–256 µg/mL). Patients admitted to the SICU for >48 h who were colonized with mupirocin-resistant MRSA were more likely to have been admitted to our hospital during the previous year (P = .016), were older (P = .009), and had higher in-hospital mortality (16% vs. 33%; P = .027), compared with patients colonized with mupirocin-susceptible MRSA. Molecular analysis of the mupirocin-resistant isolates revealed that 72.5% of isolates contained staphylococcal cassette chromosome mec II. Repetitive sequence polymerase chain reaction typing revealed that high-level mupirocin resistance was present in multiple clonal groups. The rate of mupirocin use hospital-wide during the study period was 6.08 treatment-days per 1000 patient-days. Conclusions. We documented a high rate of mupirocin resistance in MRSA isolates from SICU patients, despite low levels of in-hospital mupirocin use.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Articles and Commentaries</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Carrier State - microbiology</subject><subject>Clinical outcomes</subject><subject>Decolonization</subject><subject>Drug resistance</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Female</subject><subject>Hospital admissions</subject><subject>Hospitals, Private - statistics & numerical data</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Intensive care</subject><subject>Intensive Care Units - statistics & numerical data</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methicillin Resistance</subject><subject>Methicillin resistant staphylococcus aureus</subject><subject>Microbial colonization</subject><subject>Middle Aged</subject><subject>Missouri - epidemiology</subject><subject>Mupirocin - pharmacology</subject><subject>Nose - microbiology</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Phylogeny</subject><subject>Polymerase chain reaction</subject><subject>Risk Factors</subject><subject>Sentinel Surveillance</subject><subject>Skin diseases</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Staphylococcal Infections - epidemiology</subject><subject>Staphylococcal infections, streptococcal infections, pneumococcal infections</subject><subject>Staphylococcus</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - classification</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Staphylococcus aureus - genetics</subject><subject>Staphylococcus infections</subject><subject>Surgical intensive care units</subject><issn>1058-4838</issn><issn>1537-6591</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNp1kVFrFDEUhQdRbK36C0SioG-jSSbJJI91UFvYolgL4kvIZu-4WWeTMcmoFfzvZpl1C4JPN-F-OTfn3Kp6SPALgqV4ySkWorlVHRPetLXgitwuZ8xlzWQjj6p7KW0wJkRifrc6Iq2QVElxXP2-mEYXg3UefYDkUjbeAiq39yY78DmhLgzBu1-wQj9cXqMLyGtn3TA4X_99kdFlNuP6egg2WDslZKYIpRQZgy6n-MVZM6Bzn8En9x1QZyKgK-_y_epOb4YED_b1pLp68_pjd1Yv3r09704XtWWc5FqJpe25lIIuMVtaplTx2psWEygmBKE9AOV4BbQnlK0EIY1o20YRgnsm2mVzUj2fdccYvk2Qst66ZGEYjIcwJS0kYYy3soBP_wE3YYq-_E1TohTnTLEbNRtDShF6PUa3NfFaE6x329DzNgr4eK82LbewusH28Rfg2R4wqUTUx5K-SweOYqqwancTn8xcmMb_D3s0M5uUQzxQjEnO8c5ZPbfLxuDnoW3iVy3apuX67NPn4nFB-SssdNf8AY-Xszo</recordid><startdate>20070901</startdate><enddate>20070901</enddate><creator>Jones, Jeffrey C.</creator><creator>Rogers, Theodore J.</creator><creator>Brookmeyer, Peter</creator><creator>Dunne, William Michael</creator><creator>Storch, Gregory A.</creator><creator>Coopersmith, Craig M.</creator><creator>Fraser, Victoria J.</creator><creator>Warren, David K.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20070901</creationdate><title>Mupirocin Resistance in Patients Colonized with Methicillin-Resistant Staphylococcus aureus in a Surgical Intensive Care Unit</title><author>Jones, Jeffrey C. ; Rogers, Theodore J. ; Brookmeyer, Peter ; Dunne, William Michael ; Storch, Gregory A. ; Coopersmith, Craig M. ; Fraser, Victoria J. ; Warren, David K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-96bcf58862b04bc499663fa701e986612fee250de2f124d611367739110f467b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Articles and Commentaries</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Carrier State - microbiology</topic><topic>Clinical outcomes</topic><topic>Decolonization</topic><topic>Drug resistance</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Female</topic><topic>Hospital admissions</topic><topic>Hospitals, Private - statistics & numerical data</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Intensive care</topic><topic>Intensive Care Units - statistics & numerical data</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methicillin Resistance</topic><topic>Methicillin resistant staphylococcus aureus</topic><topic>Microbial colonization</topic><topic>Middle Aged</topic><topic>Missouri - epidemiology</topic><topic>Mupirocin - pharmacology</topic><topic>Nose - microbiology</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Phylogeny</topic><topic>Polymerase chain reaction</topic><topic>Risk Factors</topic><topic>Sentinel Surveillance</topic><topic>Skin diseases</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Staphylococcal Infections - epidemiology</topic><topic>Staphylococcal infections, streptococcal infections, pneumococcal infections</topic><topic>Staphylococcus</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - classification</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Staphylococcus aureus - genetics</topic><topic>Staphylococcus infections</topic><topic>Surgical intensive care units</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jones, Jeffrey C.</creatorcontrib><creatorcontrib>Rogers, Theodore J.</creatorcontrib><creatorcontrib>Brookmeyer, Peter</creatorcontrib><creatorcontrib>Dunne, William Michael</creatorcontrib><creatorcontrib>Storch, Gregory A.</creatorcontrib><creatorcontrib>Coopersmith, Craig M.</creatorcontrib><creatorcontrib>Fraser, Victoria J.</creatorcontrib><creatorcontrib>Warren, David K.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jones, Jeffrey C.</au><au>Rogers, Theodore J.</au><au>Brookmeyer, Peter</au><au>Dunne, William Michael</au><au>Storch, Gregory A.</au><au>Coopersmith, Craig M.</au><au>Fraser, Victoria J.</au><au>Warren, David K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mupirocin Resistance in Patients Colonized with Methicillin-Resistant Staphylococcus aureus in a Surgical Intensive Care Unit</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2007-09-01</date><risdate>2007</risdate><volume>45</volume><issue>5</issue><spage>541</spage><epage>547</epage><pages>541-547</pages><issn>1058-4838</issn><issn>1537-6591</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>Background. Nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) can be a precursor to serious infection, and decolonization with topical mupirocin has been studied as a means of preventing clinical infection. Mupirocin resistance in patients with MRSA has been reported, usually in the context of widespread mupirocin use. Methods. Patients admitted to a surgical intensive care unit (SICU) had nasal swab cultures for MRSA performed at admission, weekly, and at discharge in an active surveillance program. Collected MRSA isolates were tested for mupirocin resistance, and molecular analysis was performed. Clinical data on the characteristics and outcomes of the patients who stayed in the SICU for >48 h were collected prospectively. Results. Of the 302 MRSA isolates available for testing, 13.2% were resistant to mupirocin, with 8.6% having high-level resistance (minimum inhibitory concentration, ⩾512 µg/mL) and 4.6% having low-level resistance (minimum inhibitory concentration, 8–256 µg/mL). Patients admitted to the SICU for >48 h who were colonized with mupirocin-resistant MRSA were more likely to have been admitted to our hospital during the previous year (P = .016), were older (P = .009), and had higher in-hospital mortality (16% vs. 33%; P = .027), compared with patients colonized with mupirocin-susceptible MRSA. Molecular analysis of the mupirocin-resistant isolates revealed that 72.5% of isolates contained staphylococcal cassette chromosome mec II. Repetitive sequence polymerase chain reaction typing revealed that high-level mupirocin resistance was present in multiple clonal groups. The rate of mupirocin use hospital-wide during the study period was 6.08 treatment-days per 1000 patient-days. Conclusions. We documented a high rate of mupirocin resistance in MRSA isolates from SICU patients, despite low levels of in-hospital mupirocin use.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>17682986</pmid><doi>10.1086/520663</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1058-4838 |
ispartof | Clinical infectious diseases, 2007-09, Vol.45 (5), p.541-547 |
issn | 1058-4838 1537-6591 1537-6591 |
language | eng |
recordid | cdi_proquest_miscellaneous_68144578 |
source | JSTOR Archival Journals and Primary Sources Collection; Oxford Journals Online |
subjects | Adolescent Adult Aged Aged, 80 and over Anti-Bacterial Agents - pharmacology Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Articles and Commentaries Bacterial diseases Biological and medical sciences Carrier State - microbiology Clinical outcomes Decolonization Drug resistance Drug Resistance, Multiple, Bacterial Female Hospital admissions Hospitals, Private - statistics & numerical data Human bacterial diseases Humans Infections Infectious diseases Intensive care Intensive Care Units - statistics & numerical data Male Medical sciences Methicillin Resistance Methicillin resistant staphylococcus aureus Microbial colonization Middle Aged Missouri - epidemiology Mupirocin - pharmacology Nose - microbiology Patients Pharmacology. Drug treatments Phylogeny Polymerase chain reaction Risk Factors Sentinel Surveillance Skin diseases Staphylococcal Infections - drug therapy Staphylococcal Infections - epidemiology Staphylococcal infections, streptococcal infections, pneumococcal infections Staphylococcus Staphylococcus aureus Staphylococcus aureus - classification Staphylococcus aureus - drug effects Staphylococcus aureus - genetics Staphylococcus infections Surgical intensive care units |
title | Mupirocin Resistance in Patients Colonized with Methicillin-Resistant Staphylococcus aureus in a Surgical Intensive Care Unit |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A42%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mupirocin%20Resistance%20in%20Patients%20Colonized%20with%20Methicillin-Resistant%20Staphylococcus%20aureus%20in%20a%20Surgical%20Intensive%20Care%20Unit&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Jones,%20Jeffrey%20C.&rft.date=2007-09-01&rft.volume=45&rft.issue=5&rft.spage=541&rft.epage=547&rft.pages=541-547&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/520663&rft_dat=%3Cjstor_proqu%3E4485508%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c451t-96bcf58862b04bc499663fa701e986612fee250de2f124d611367739110f467b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=219955494&rft_id=info:pmid/17682986&rft_jstor_id=4485508&rft_oup_id=10.1086/520663&rfr_iscdi=true |